A composition for controlling or preventing progression of glaucoma comprisesa material that reduces or inhibits production of a TGF-β isoform or a chemokineor cytokine that stimulates expression of a TGF-β isoform. The materialcan comprise a dissociated glucocorticoid receptor agonist ("DIGRA"),a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceuticallyacceptable ester thereof. The composition can further comprise an antagonistto TGF-β. It is administered to a patient who has undergone glaucoma filtrationsurgery to ensure a functioning filtering bleb following such surgery.
